NCT04706910 - 18F-DOPA II - PET Imaging Optimization | Biotech Hunter

Enrollment

800

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions

Congenital HyperinsulinismNeuroblastomaParkinson DiseaseLewy Body DiseaseNeuroendocrine TumorsBrain Tumor

Interventions

DRUG

18F-DOPA

All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study

DRUG

Furosemide Injection

Some participants will receive an intravenous injection of furosemide (40mg, single dose)

Trial Locations (1)

RECRUITING

WC Mackenzie Health Science Centre / University of Alberta Hospital, Edmonton

All Listed Sponsors

lead

University of Alberta

OTHER